Suppr超能文献

简短报告:转移性葡萄膜黑色素瘤中的变异

Short Report: The Variants in in Metastatic Uveal Melanoma.

作者信息

Terai Mizue, Seedor Rino, Ashraf Usman, Hubbard Gretchen, Koshkin Sergei, Orloff Marlana, Sato Takami

机构信息

Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia, PA 19107, USA.

Caris Life Sciences, Irving, TX 75039, USA.

出版信息

J Clin Med. 2025 Apr 18;14(8):2815. doi: 10.3390/jcm14082815.

Abstract

Uveal melanoma (UM) is a rare subtype of melanoma with distinct clinical and molecular features compared to other melanoma subtypes. UM tumors are frequently detected with mutations in , , , , and instead of the typical mutations associated with cutaneous melanoma. Although hereditary UM is rare, germline loss predisposes patients to UM and various other cancers. The (Checkpoint kinase 2) gene that encodes the protein CHK2, a serine-threonine kinase, is a cell cycle checkpoint regulator that acts as a tumor suppressor. CHK2 is involved in DNA repair, cell cycle arrest, or apoptosis in response to DNA damage. mutations have been linked to various cancers. While there is no strong evidence that mutations increase the risk of melanoma, two cases of germline mutations in UM patients have been reported. However, the incidence of variants in metastatic UM (MUM) has not been investigated. Thus, we conducted a retrospective analysis of patients with MUM and variants to understand this link better. We collected MUM cases from 2016 to 2024 from institutional databases. Tissues underwent analyses of molecular and genomic features, including tumor mutational burden, and were performed by a Clinically Certified Laboratory. Next-generation sequencing and variant calling were conducted to identify variants. In this study, we reported ten patients with variants among 740 metastatic UM patients (1.4%) and four primary UM patients with germline mutations. Although rare, UM patients with an abnormal ATM-CHEK2 axis might receive clinical benefits from medications that target DNA repair mechanisms.

摘要

葡萄膜黑色素瘤(UM)是黑色素瘤的一种罕见亚型,与其他黑色素瘤亚型相比具有独特的临床和分子特征。UM肿瘤经常检测到 、 、 、 和 基因的突变,而非与皮肤黑色素瘤相关的典型突变。虽然遗传性UM很罕见,但种系 缺失使患者易患UM和其他多种癌症。编码丝氨酸 - 苏氨酸激酶CHK2的 (细胞周期检查点激酶2)基因是一种细胞周期检查点调节因子,起肿瘤抑制作用。CHK2参与DNA损伤后的DNA修复、细胞周期停滞或凋亡。 突变与多种癌症有关。虽然没有确凿证据表明 突变会增加黑色素瘤风险,但已报道两例UM患者发生种系 突变的病例。然而,转移性UM(MUM)中 变异的发生率尚未得到研究。因此,我们对MUM患者和 变异进行了回顾性分析,以更好地了解这种关联。我们从机构数据库收集了2016年至2024年的MUM病例。组织进行了分子和基因组特征分析,包括肿瘤突变负荷分析,由临床认证实验室进行。进行了二代测序和变异检测以识别 变异。在本研究中,我们报告了740例转移性UM患者中有10例(1.4%)存在 变异,以及4例原发性UM患者存在 种系突变。虽然罕见,但ATM - CHEK2轴异常的UM患者可能从靶向DNA修复机制的药物中获得临床益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0990/12028195/6fcc542d3ea3/jcm-14-02815-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验